Australia's most trusted
source of pharma news
Thursday, 06 November 2025
Posted 4 November 2025 PM
Big changes at Johnson & Johnson spin-off Kenvue with the ANZ Managing Director Nadia Stone departing - as well as Kimberly-Clark today unveiling plans to buy the company in a deal worth just under $75 billion (US$48.7 billion).
Stone has led Kenvue since J&J separated from its consumer healthcare business in August 2023. Prior to that she had been with J&J for almost 10 years.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.